Reply To: Ocrelizumab – a breakthrough?

I have a dear friend with severe progressive MS. Over the years I’ve watched her go from an active person to someone confined to a wheelchair and unable to use her hands. Ocrevus is apparently ineffective against that form of the disease, and my friend has not received the drug in the two years since it was approved. It is effective against the relapsing/remitting form. That makes me hopeful it will eventually be used for CIDP, which of course is a relapsing/remitting neurological disease. The list price in the US is $65,000 for two infusions a year (that’s the standard way of giving it), but almost nobody pays that much.